Breast Cancer

The European Medicines Agency has validated a Marketing Authorization application for sacituzumab govitecan-hziy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who had previously received at least 2 therapies, including at least 1 therapy for locally advanced or metastatic disease.

Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Patrick Borgen, MD, discusses common symptoms of breast cancer in male patients.

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Adam M. Brufsky, MD, PhD, discusses treatment options for male patients with breast cancer.

Patrick I. Borgen, MD, discusses male breast cancer in further detail, how he approaches treatment in his male patients with the disease, and what can be done to remove the stigma that men often feel with a breast cancer diagnosis.

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

José Baselga, MD, PhD, a breast cancer pioneer and executive vice president of oncology R&D at AstraZeneca, passed away on Sunday at the age of 61.

Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.

Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Findings from recent analyses have kindled hope that novel agents with manageable toxicity profiles may begin to bridge the gap for patients with HER2-positive metastatic breast cancer.

Although the majority of the patient population is made up of women, males represent 1 in 100 cases diagnosed in the United States each year.

Patrick Borgen, MD, discusses the prognosis of breast cancer in male patients.

Javier Cortés, MD, PhD, discusses the incidence and management of male patients with breast cancer in Spain.

Sara A. Hurvitz, MD, discusses the incidence of male breast cancer in the United States.

Aditya Bardia, MD, MPH, discusses the integration of ADCs and immunotherapy into the treatment landscape in metastatic TNBC and the future of AKT inhibitors in the field.

Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.

Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

The FDA's accelerated approval of sacituzumab govitecan-hziy in April 2020, filled a previously undefined role for antibody-drug conjugates in patients with triple-negative breast cancer.

The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.

Prognosis and treatment recommendations for patients with breast cancer and brain metastases rely heavily on the tumor subtype; however, evolving evidence demonstrates that receptor expression and subtype grouping may change during the course of the patient’s disease.

There are a number of strategies to reduce margin positivity, particularly after partial mastectomy, but the relative effectiveness of each varies, as do the data that support their use.